top of page

Our Story

ClearSky Medical Diagnostics specialises in developing digital technologies for the diagnosis and monitoring of Parkinson’s, Alzheimer’s, and other neurodegenerative conditions.


Originating from a collaboration with specialists from Leeds General Infirmary, Heriot-Watt University, and the University of York, the company was incorporated in 2013 by co-founder and director Dr. Stephen Smith, along with academic and industry investors.

In response to the stagnant diagnostic landscape of neurodegenerative conditions, ClearSky was founded on the vision of transforming healthcare through modern technologies and computer science. Our mission is to provide objective tools for assessing and monitoring these conditions, addressing challenges in accessibility and introducing clarity to medical diagnoses—reflecting our name, ClearSky, in understanding neuroscience. Over the past ten years, ClearSky has created a portfolio of non-invasive devices for safe, quick, and objective symptom assessment, making them ideal for clinical diagnostics and supporting research. Leveraging broad expertise in AI & Machine Learning, wearable technologies, clinical domains, and crucial commercialization aspects like regulatory affairs and pricing, ClearSky offers tailored, comprehensive AI/Machine Learning services for healthcare professionals and industry stakeholders seeking digital technology solutions.

Management Team

AI and Machine Learning Team

Medical Advisers

Get in Touch

ClearSky Medical Diagnostics
The Catalyst
Baird Lane

YO10 5GA
+44 (0)1904 322351

  • Facebook
  • Twitter
  • LinkedIn

Thanks for your inquiry!

bottom of page